Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Samnick S, Maasjosthusmann U, Lerch H, Gildehaus F J, Wassmann H, Schober O
Department of Nuclear Medicine, Westfälische Wilhelms-Universität Münster, Germany.
Eur J Nucl Med. 1996 Oct;23(10):1345-53. doi: 10.1007/BF01367590.
Using single-photon emission tomography (SPET), the radiopharmaceutical l-3-iodine-123-alpha-methyl tyrosine (IMT) has been applied to the imaging of amino acid transport into brain tumours. It was the aim of this study to investigate whether IMT SPET is capable of differentiating between high-grade gliomas, low-grade gliomas and non-neoplastic brain lesions. To this end, IMT uptake was determined in 53 patients using the triple-headed SPET camera MULTISPECT 3. Twenty-eight of these subjects suffered from high-grade gliomas (WHO grade III or IV), 12 from low-grade gliomas (WHO grade II), and 13 from non-neoplastic brain lesions, including lesions after effective therapy of a glioma (five cases), infarctions (four cases), inflammatory lesions (three cases) and traumatic haematoma (one case). IMT uptake was significantly higher in high-grade gliomas than in low-grade gliomas and non-neoplastic lesions. IMT uptake by low-grade gliomas was not significantly different from that by non-neoplastic lesions. Diagnostic sensitivity and specificity were 71% and 83% for differentiating high-grade from low-grade gliomas, 82% and 100% for distinguishing high-grade gliomas from non-neoplastic lesions, and 50% and 100% for discriminating low-grade gliomas from non-neoplastic lesions. Analogously to positron emission tomography with radioactively labelled amino acids and fluorine-18 deoxyglucose, IMT SPET may aid in differentiating high-grade gliomas from histologically benign brain tumours and non-neoplastic brain lesions; it is of only limited value in differentiating between non-neoplastic lesions and histologically benign brain tumours.
利用单光子发射断层扫描（SPET），放射性药物l-3-碘-123-α-甲基酪氨酸（IMT）已被应用于脑肿瘤氨基酸转运成像。本研究的目的是调查IMT SPET是否能够区分高级别胶质瘤、低级别胶质瘤和非肿瘤性脑病变。为此，使用三头SPET相机MULTISPECT 3对53例患者的IMT摄取情况进行了测定。其中28例受试者患有高级别胶质瘤（世界卫生组织III级或IV级），12例患有低级别胶质瘤（世界卫生组织II级），13例患有非肿瘤性脑病变，包括胶质瘤有效治疗后的病变（5例）、梗死（4例）、炎症性病变（3例）和外伤性血肿（1例）。高级别胶质瘤中的IMT摄取显著高于低级别胶质瘤和非肿瘤性病变。低级别胶质瘤的IMT摄取与非肿瘤性病变的IMT摄取无显著差异。区分高级别与低级别胶质瘤的诊断敏感性和特异性分别为71%和83%，区分高级别胶质瘤与非肿瘤性病变的诊断敏感性和特异性分别为82%和100%，区分低级别胶质瘤与非肿瘤性病变的诊断敏感性和特异性分别为50%和100%。与使用放射性标记氨基酸和氟-18脱氧葡萄糖的正电子发射断层扫描类似，IMT SPET可能有助于区分高级别胶质瘤与组织学上良性的脑肿瘤和非肿瘤性脑病变；在区分非肿瘤性病变与组织学上良性的脑肿瘤方面，其价值有限。
